Glycogen metabolism in humans

BBA Clinical

Volumn 5, Issue , 2016, Pages 85-100

  Adeva Andany, María M ^a   González Lucán, Manuel ^a   Donapetry García, Cristóbal ^a   Fernández Fernández, Carlos ^a   Ameneiros Rodríguez, Eva ^a  

^a Hospital General Juan Cardona   (Spain)

Author keywords

Glucokinase; Glucose; Glycogen phosphorylase; Glycogen storage diseases; Glycogen synthase; Phosphoglucomutases; Glucosidase

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ALPHA GLUCOSIDASE; ENOLASE; GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 4; GLYCOGEN DEBRANCHING ENZYME; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE; GLYCOGENIN; LACTATE DEHYDROGENASE; LAFORIN; MALIN; N ACETYLGLUCOSAMINE; PEPTIDES AND PROTEINS; PHOSPHOGLUCOMUTASE; PHOSPHOGLYCERATE MUTASE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHORYLASE KINASE; PRDM8 PROTEIN; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCOSE;

BLOOD BRAIN BARRIER; CARDIOVASCULAR DISEASE; DEPHOSPHORYLATION; ENZYME ACTIVITY; ENZYME REGULATION; EXERCISE TOLERANCE; GENE MUTATION; GLUCOSE TRANSPORT; GLUCOSURIA; GLYCOGEN METABOLISM; GLYCOGEN STORAGE DISEASE TYPE 4; GLYCOGEN STORAGE DISEASE TYPE 5; GLYCOGEN STORAGE DISEASE TYPE 6; GLYCOGEN STORAGE DISEASE TYPE 7; GLYCOGEN STORAGE DISEASE TYPE 8; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; GLYCOSYLATION; HUMAN; HYPERGLYCEMIA; HYPERLACTATEMIA; ISOMERIZATION; KETOGENIC DIET; LACTIC ACIDEMIA; LYSOSOME; MYOCLONUS EPILEPSY; PRIORITY JOURNAL; REVIEW;

EID: 84960103464     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2016.02.001     Document Type: Review

References (133)

1. Chikwana V.M., Khanna M., Baskaran S., et al. Structural basis for 2[U+02B9]-phosphate incorporation into glycogen by glycogen synthase. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(52):20976-20981.
2. De Giorgis V., Veggiotti P. GLUT1 deficiency syndrome 2013: current state of the art. Seizure 2013, 22(10):803-811.
3. Scholl-Bürgi S., Höller A., Pichler K., Michel M., Haberlandt E., Karall D. Ketogenic diets in patients with inherited metabolic disorders. J. Inherit. Metab. Dis. 2015, 38(4):765-773.
4. Gottesman I., Mandarino L., Gerich J. Estimation and kinetic analysis of insulin-independent glucose uptake in human subjects. Am. J. Physiol. 1983, 244(6):E632-E635.
5. Lauritzen H.P., Schertzer J.D. Measuring GLUT4 translocation in mature muscle fibers. Am. J. Physiol. Endocrinol. Metab. 2010, 299(2):E169-E179.
6. Jensen J., Rustad P.I., Kolnes A.J., Lai Y.C. The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise. Front. Physiol. 2011, 2:112.
7. Akagi M., Inui K., Nakajima S., et al. Mutation analysis of two Japanese patients with Fanconi-Bickel syndrome. J. Hum. Genet. 2000, 45(1):60-62.
8. Santer R., Schneppenheim R., Suter D., Schaub J., Steinmann B. Fanconi-Bickel syndrome-the original patient and his natural history, historical steps leading to the primary defect, and a review of the literature. Eur. J. Pediatr. 1998, 157(10):783-797.
9. Lehto M., Xiang K., Stoffel M., et al. Human hexokinase II: localization of the polymorphic gene to chromosome 2. Diabetologia 1993, 36(12):1299-1302.
10. Bedoya F.J., Wilson J.M., Ghosh A.K., Finegold D., Matschinsky F.M. The glucokinase glucose sensor in human pancreatic islet tissue. Diabetes 1986, 35(1):61-67.
11. Pilkis S.J., Weber I.T., Harrison R.W., Bell G.I. Glucokinase: structural analysis of a protein involved in susceptibility to diabetes. J. Biol. Chem. 1994, 269(35):21925-21928.
12. Lenzen S. A fresh view of glycolysis and glucokinase regulation: history and current status. J. Biol. Chem. 2014, 289(18):12189-12194.
13. Beck T., Miller B.G. Structural basis for regulation of human glucokinase by glucokinase regulatory protein. Biochemistry 2013, 52(36):6232-6239.
14. Raimondo A., Rees M.G., Gloyn A.L. Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism. Curr. Opin. Lipidol. 2015, 26(2):88-95.
15. Velho G., Petersen K.F., Perseghin G., et al. Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. J. Clin. Invest. 1996, 98(8):1755-1761.
16. Putt W., Ives J.H., Hollyoake M., Hopkinson D.A., Whitehouse D.B., Edwards Y.H. Phosphoglucomutase 1: a gene with two promoters and a duplicated first exon. Biochem. J. 1993, 296(Pt 2):417-422.
17. Edwards Y.H., Putt W., Fox M., Ives J.H. A novel human phosphoglucomutase (PGM5) maps to the centromeric region of chromosome 9. Genomics 1995, 30(2):350-353.
18. Stojkovic T., Vissing J., Petit F., et al. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N. Engl. J. Med. 2009, 361(4):425-427.
19. Lee Y., Stiers K.M., Kain B.N., Beamer L.J. Compromised catalysis and potential folding defects in in vitro studies of missense mutants associated with hereditary phosphoglucomutase 1 deficiency. J. Biol. Chem. 2014, 289(46):32010-32019.
20. Tegtmeyer L.C., Rust S., van Scherpenzeel M., et al. Multiple phenotypes in phosphoglucomutase 1 deficiency. N. Engl. J. Med. 2014, 370(6):533-542.
21. Morava E. Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG. Mol. Genet. Metab. 2014, 112(4):275-279.
22. Pang H., Koda Y., Soejima M., Kimura H. Identification of human phosphoglucomutase 3 (PGM3) as N-acetylglucosamine-phosphate mutase (AGM1). Ann. Hum. Genet. 2002, 66(Pt 2):139-144.
23. Sassi A., Lazaroski S., Wu G., et al. Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. J. Allergy Clin. Immunol. 2014, 133(5):1410-1419. (1419.e1411-1413).
24. Zhang Y., Yu X., Ichikawa M., et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J. Allergy Clin. Immunol. 2014, 133(5):1400-1409. (1409.e1401-1405).
25. Yu Q., Zheng X. The crystal structure of human UDP-glucose pyrophosphorylase reveals a latch effect that influences enzymatic activity. Biochem. J. 2012, 442(2):283-291.
26. Peng H.L., Chang H.Y. Cloning of a human liver UDP-glucose pyrophosphorylase cDNA by complementation of the bacterial galU mutation. FEBS Lett. 1993, 329(1-2):153-158.
27. Van Someren H., Van Henegouwen H.B., Westerveld A., Bootsma D. Synteny of the human loci for fumarate hydratase and udpg pyrophosphorylase with chromosome 1 markers in somatic cell hybrids. Cytogenet. Cell Genet. 1974, 13(6):551-557.
28. Cheng S.D., Peng H.L., Chang H.Y. Localization of the human UGP2 gene encoding the muscle isoform of UDPglucose pyrophosphorylase to 2p13-p14 by fluorescence in situ hybridization. Genomics 1997, 39(3):414-416.
29. Gibbons B.J., Roach P.J., Hurley T.D. Crystal structure of the autocatalytic initiator of glycogen biosynthesis, glycogenin. J. Mol. Biol. 2002, 319(2):463-477.
30. Barbetti F., Rocchi M., Bossolasco M., et al. The human skeletal muscle glycogenin gene: cDNA, tissue expression and chromosomal localization. Biochem. Biophys. Res. Commun. 1996, 220(1):72-77.
31. Mu J., Roach P.J. Characterization of human glycogenin-2, a self-glucosylating initiator of liver glycogen metabolism. J. Biol. Chem. 1998, 273(52):34850-34856.
32. Moslemi A.R., Lindberg C., Nilsson J., Tajsharghi H., Andersson B., Oldfors A. Glycogenin-1 deficiency and inactivated priming of glycogen synthesis. N. Engl. J. Med. 2010, 362(13):1203-1210.
33. Malfatti E., Nilsson J., Hedberg-Oldfors C., et al. A new muscle glycogen storage disease associated with glycogenin-1 deficiency. Ann. Neurol. 2014, 76(6):891-898.
34. Nielsen J.N., Richter E.A. Regulation of glycogen synthase in skeletal muscle during exercise. Acta Physiol. Scand. 2003, 178(4):309-319.
35. Lehto M., Stoffel M., Groop L., Espinosa R., Le Beau M.M., Bell G.I. Assignment of the gene encoding glycogen synthase (GYS) to human chromosome 19, band q13.3. Genomics 1993, 15(2):460-461.
36. Nuttall F.Q., Gannon M.C., Kubic V.L., Hoyt K.J. The human liver Glycogen synthase isozyme gene is located on the short arm of chromosome 12. Genomics 1994, 19(2):404-405.
37. Cameron J.M., Levandovskiy V., MacKay N., et al. Identification of a novel mutation in GYS1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts. Mol. Genet. Metab. 2009, 98(4):378-382.
38. Weinstein D.A., Correia C.E., Saunders A.C., Wolfsdorf J.I. Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia. Mol. Genet. Metab. 2006, 87(4):284-288.
39. Nielsen J.N., Wojtaszewski J.F., Haller R.G., et al. Role of 5[U+02B9]AMP-activated protein kinase in glycogen synthase activity and glucose utilization: insights from patients with McArdle's disease. J. Physiol. 2002, 541(Pt 3):979-989.
40. Blair E., Redwood C., Ashrafian H., et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 2001, 10(11):1215-1220.
41. Arad M., Benson D.W., Perez-Atayde A.R., et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J. Clin. Invest. 2002, 109(3):357-362.
42. Aggarwal V., Dobrolet N., Fishberger S., Zablah J., Jayakar P., Ammous Z. PRKAG2 mutation: an easily missed cardiac specific non-lysosomal glycogenosis. Ann. Pediatr. Cardiol. 2015, 8(2):153-156.
43. Ragolia L., Begum N. Protein phosphatase-1 and insulin action. Mol. Cell. Biochem. 1998, 182(1-2):49-58.
44. Akman H.O., Kakhlon O., Coku J., et al. Deep intronic GBE1 mutation in manifesting heterozygous patients with adult polyglucosan body disease. JAMA Neurol. 2015, 72(4):441-445.
45. Magoulas P.L., El-Hattab A.W., Roy A., Bali D.S., Finegold M.J., Craigen W.J. Diffuse reticuloendothelial system involvement in type IV glycogen storage disease with a novel GBE1 mutation: a case report and review. Hum. Pathol. 2012, 43(6):943-951.
46. Aksu T., Colak A., Tufekcioglu O. Cardiac involvement in glycogen storage disease type IV: two cases and the two ends of a spectrum. Case Rep. Med. 2012, 2012:764286.
47. Sagnelli A., Savoiardo M., Marchesi C., et al. Adult polyglucosan body disease in a patient originally diagnosed with Fabry's disease. Neuromuscul. Disord. 2014, 24(3):272-276.
48. Bao Y., Kishnani P., Wu J.Y., Chen Y.T. Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. J. Clin. Invest. 1996, 97(4):941-948.
49. Mochel F., Schiffmann R., Steenweg M.E., et al. Adult polyglucosan body disease: natural history and key magnetic resonance imaging findings. Ann. Neurol. 2012, 72(3):433-441.
50. Billot S., Herve D., Akman H.O., et al. Acute but transient neurological deterioration revealing adult polyglucosan body disease. J. Neurol. Sci. 2013, 324(1-2):179-182.
51. Gentry M.S., Worby C.A., Dixon J.E. Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(24):8501-8506.
52. Sankhala R.S., Koksal A.C., Ho L., Nitschke F., Minassian B.A., Cingolani G. Dimeric quaternary structure of human laforin. J. Biol. Chem. 2015, 290(8):4552-4559.
53. Minassian B.A., Ianzano L., Meloche M., et al. Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology 2000, 55(3):341-346.
54. Ianzano L., Zhang J., Chan E.M., et al. Lafora progressive myoclonus epilepsy mutation database-EPM2A and NHLRC1 (EPM2B) genes. Hum. Mutat. 2005, 26(4):397.
55. Turnbull J., Girard J.M., Lohi H., et al. Early-onset Lafora body disease. Brain 2012, 135(Pt 9):2684-2698.
56. Burwinkel B., Bakker H.D., Herschkovitz E., Moses S.W., Shin Y.S., Kilimann M.W. Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI. Am. J. Hum. Genet. 1998, 62(4):785-791.
57. Kato K., Shimizu A., Kurobe N., Takashi M., Koshikawa T. Human brain-type glycogen phosphorylase: quantitative localization in human tissues determined with an immunoassay system. J. Neurochem. 1989, 52(5):1425-1432.
58. Newgard C.B., Littman D.R., van Genderen C., Smith M., Fletterick R.J. Human brain glycogen phosphorylase. Cloning, sequence analysis, chromosomal mapping, tissue expression, and comparison with the human liver and muscle isozymes. J. Biol. Chem. 1988, 263(8):3850-3857.
59. Orngreen M.C., Jeppesen T.D., Taivassalo T., et al. Lactate and energy metabolism during exercise in patients with blocked glycogenolysis (McArdle disease). J. Clin. Endocrinol. Metab. 2015.
60. Orngreen M.C., Jeppesen T.D., Andersen S.T., et al. Fat metabolism during exercise in patients with McArdle disease. Neurology 2009, 72(8):718-724.
61. Wagenmakers A.J., Coakley J.H., Edwards R.H. Metabolism of branched-chain amino acids and ammonia during exercise: clues from McArdle's disease. Int. J. Sports Med. 1990, 11(Suppl. 2):S101-S113.
62. Petrou P., Pantzaris M., Dionysiou M., Drousiotou A., Kyriakides T. Minimally symptomatic McArdle disease, expanding the genotype-phenotype spectrum. Muscle Nerve 2015.
63. Quinlivan R., Martinuzzi A., Schoser B. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Syst. Rev. 2014, 11.
64. Newgard C.B., Fletterick R.J., Anderson L.A., Lebo R.V. The polymorphic locus for glycogen storage disease VI (liver glycogen phosphorylase) maps to chromosome 14. Am. J. Hum. Genet. 1987, 40(4):351-364.
65. Roscher A., Patel J., Hewson S., et al. The natural history of glycogen storage disease types VI and IX: Long-term outcome from the largest metabolic center in Canada. Mol. Genet. Metab. 2014, 113(3):171-176.
66. Ercan-Fang N., Gannon M.C., Rath V.L., Treadway J.L., Taylor M.R., Nuttall F.Q. Integrated effects of multiple modulators on human liver glycogen phosphorylase a. Am. J. Physiol. Endocrinol. Metab. 2002, 283(1):E29-E37.
67. Rath V.L., Ammirati M., LeMotte P.K., et al. Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core. Mol. Cell 2000, 6(1):139-148.
68. Munger R., Temler E., Jallut D., Haesler E., Felber J.P. Correlations of glycogen synthase and phosphorylase activities with glycogen concentration in human muscle biopsies. Evidence for a double-feedback mechanism regulating glycogen synthesis and breakdown. Metabolism 1993, 42(1):36-43.
69. Keppens S., Vandekerckhove A., Moshage H., Yap S.H., Aerts R., De Wulf H. Regulation of glycogen phosphorylase activity in isolated human hepatocytes. Hepatology 1993, 17(4):610-614.
70. Bali D.S., Goldstein J.L., Fredrickson K., et al. Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene. Mol. Genet. Metab. 2014, 111(3):309-313.
71. Beauchamp N.J., Dalton A., Ramaswami U., et al. Glycogen storage disease type IX: high variability in clinical phenotype. Mol. Genet. Metab. 2007, 92(1-2):88-99.
72. Orngreen M.C., Schelhaas H.J., Jeppesen T.D., et al. Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency?. Neurology 2008, 70(20):1876-1882.
73. Echaniz-Laguna A., Akman H.O., Mohr M., et al. Muscle phosphorylase b kinase deficiency revisited. Neuromuscul. Disord. 2010, 20(2):125-127.
74. Mizuta K., Hashimoto E., Tsutou A., et al. A new type of glycogen storage disease caused by deficiency of cardiac phosphorylase kinase. Biochem. Biophys. Res. Commun. 1984, 119(2):582-587.
75. Bührer C., van Landeghem F.K., Felderhoff-Mueser U., Stadelmann C., Obladen M. Fetal bradycardia at 28 weeks of gestation associated with cardiac glycogen phosphorylase b kinase deficiency. Acta Paediatr. 2003, 92(11):1352-1353.
76. Chen Y.T., He J.K., Ding J.H., Brown B.I. Glycogen debranching enzyme: purification, antibody characterization, and immunoblot analyses of type III glycogen storage disease. Am. J. Hum. Genet. 1987, 41(6):1002-1015.
77. Bao Y., Dawson T.L., Chen Y.T. Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5' flanking region. Genomics 1996, 38(2):155-165.
78. Cheng A., Zhang M., Okubo M., Omichi K., Saltiel A.R. Distinct mutations in the glycogen debranching enzyme found in glycogen storage disease type III lead to impairment in diverse cellular functions. Hum. Mol. Genet. 2009, 18(11):2045-2052.
79. Guin S., Pollard C., Ru Y., et al. Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. J. Natl. Cancer Inst. 2014, 106(5).
80. Shen J., Bao Y., Liu H.M., Lee P., Leonard J.V., Chen Y.T. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J. Clin. Invest. 1996, 98(2):352-357.
81. Li X.H., Gong Q.M., Ling Y., et al. Inherent lipid metabolic dysfunction in glycogen storage disease IIIa. Biochem. Biophys. Res. Commun. 2014, 455(1-2):90-97.
82. Gershen L.D., Prayson B.E., Prayson R.A. Pathological characteristics of glycogen storage disease III in skeletal muscle. J. Clin. Neurosci. 2015.
83. Preisler N., Pradel A., Husu E., et al. Exercise intolerance in glycogen storage disease type III: weakness or energy deficiency?. Mol. Genet. Metab. 2013, 109(1):14-20.
84. Mogahed E.A., Girgis M.Y., Sobhy R., Elhabashy H., Abdelaziz O.M., El-Karaksy H. Skeletal and cardiac muscle involvement in children with glycogen storage disease type III. Eur. J. Pediatr. 2015.
85. Preisler N., Laforêt P., Madsen K.L., et al. Skeletal muscle metabolism is impaired during exercise in glycogen storage disease type III. Neurology 2015, 84(17):1767-1771.
86. Wisselaar H.A., Kroos M.A., Hermans M.M., van Beeumen J., Reuser A.J. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J. Biol. Chem. 1993, 268(3):2223-2231.
87. Tsuji A., Omura K., Suzuki Y. Intracellular transport of acid alpha-glucosidase in human fibroblasts: evidence for involvement of phosphomannosyl receptor-independent system. J. Biochem. 1988, 104(2):276-278.
88. Remiche G., Ronchi D., Magri F., et al. Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature. J. Neurol. 2014, 261(1):83-97.
89. Bali D.S., Tolun A.A., Goldstein J.L., Dai J., Kishnani P.S. Molecular analysis and protein processing in late-onset Pompe disease patients with low levels of acid alpha-glucosidase activity. Muscle Nerve 2011, 43(5):665-670.
90. Preisler N., Laforet P., Madsen K.L., et al. Fat and carbohydrate metabolism during exercise in late-onset Pompe disease. Mol. Genet. Metab. 2012, 107(3):462-468.
91. Katona I., Weis J., Hanisch F. Glycogenosome accumulation in the arrector pili muscle in Pompe disease. Orphanet J. Rare Dis. 2014, 9:17.
92. Muraoka T., Murao K., Imachi H., et al. Novel mutations in the gene encoding acid alpha-1,4-glucosidase in a patient with late-onset glycogen storage disease type II (Pompe disease) with impaired intelligence. Intern. Med. 2011, 50(24):2987-2991.
93. Kishnani P.S., Beckemeyer A.A. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Pediatr. Endocrinol. Rev. 2014, 12(Suppl. 1):114-124.
94. Mundy H.R., Williams J.E., Cousins A.J., Lee P.J. The effect of l-alanine therapy in a patient with adult onset glycogen storage disease type II. J. Inherit. Metab. Dis. 2006, 29(1):226-229.
95. Terzis G., Dimopoulos F., Papadimas G.K., et al. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol. Genet. Metab. 2011, 104(3):279-283.
96. Boucek D., Jirikowic J., Taylor M. Natural history of Danon disease. Genet. Med. 2011, 13(6):563-568.
97. Martin C.C., Oeser J.K., Svitek C.A., Hunter S.I., Hutton J.C., O'Brien R.M. Identification and characterization of a human cDNA and gene encoding a ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein. J. Mol. Endocrinol. 2002, 29(2):205-222.
98. Lin B., Pan C.J., Chou J.Y. Human variant glucose-6-phosphate transporter is active in microsomal transport. Hum. Genet. 2000, 107(5):526-529.
99. Martin C.C., Bischof L.J., Bergman B., et al. Cloning and characterization of the human and rat islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) genes. J. Biol. Chem. 2001, 276(27):25197-25207.
100. Chou J.Y., Mansfield B.C. Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum. Mutat. 2008, 29(7):921-930.
101. Jun H.S., Weinstein D.A., Lee Y.M., Mansfield B.C., Chou J.Y. Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib. Blood 2014, 123(18):2843-2853.
102. Melis D., Della Casa R., Balivo F., et al. Involvement of endocrine system in a patient affected by glycogen storage disease 1b: speculation on the role of autoimmunity. Ital. J. Pediatr. 2014, 40(1):30.
103. Ross K.M., Brown L.M., Corrado M.M., et al. Safety and efficacy of chronic extended release cornstarch therapy for glycogen storage disease type I. JIMD Rep. 2015.
104. Shah K.K., O'Dell S.D. Effect of dietary interventions in the maintenance of normoglycaemia in glycogen storage disease type 1a: a systematic review and meta-analysis. J. Hum. Nutr. Diet. 2013, 26(4):329-339.
105. Banka S., Newman W.G. A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency caused by G6PC3 mutations. Orphanet J. Rare Dis. 2013, 8(1):84.
106. Hayee B., Antonopoulos A., Murphy E.J., et al. G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunction. Glycobiology 2011, 21(7):914-924.
107. Webb B.A., Forouhar F., Szu F.E., Seetharaman J., Tong L., Barber D.L. Structures of human phosphofructokinase-1 and atomic basis of cancer-associated mutations. Nature 2015, 523(7558):111-114.
108. Al Hasawi N., Alkandari M.F., Luqmani Y.A. Phosphofructokinase: a mediator of glycolytic flux in cancer progression. Crit. Rev. Oncol. Hematol. 2014, 92(3):312-321.
109. Malfatti E., Birouk N., Romero N.B., et al. Juvenile-onset permanent weakness in muscle phosphofructokinase deficiency. J. Neurol. Sci. 2012, 316(1-2):173-177.
110. Sakoda S., Shanske S., DiMauro S., Schon E.A. Isolation of a cDNA encoding the B isozyme of human phosphoglycerate mutase (PGAM) and characterization of the PGAM gene family. J. Biol. Chem. 1988, 263(32):16899-16905.
111. Tsujino S., Shanske S., Sakoda S., Fenichel G., DiMauro S. The molecular genetic basis of muscle phosphoglycerate mutase (PGAM) deficiency. Am. J. Hum. Genet. 1993, 52(3):472-477.
112. Kreuder J., Borkhardt A., Repp R., et al. Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N. Engl. J. Med. 1996, 334(17):1100-1104.
113. Beutler E., Scott S., Bishop A., et al. Red cell aldolase deficiency and hemolytic anemia: a new syndrome. Trans. Assoc. Am. Phys. 1973, 86:154-166.
114. Comi G.P., Fortunato F., Lucchiari S., et al. Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann. Neurol. 2001, 50(2):202-207.
115. Peshavaria M., Hinks L.J., Day I.N. Structure of human muscle (beta) enolase mRNA and protein deduced from a genomic clone. Nucleic Acids Res. 1989, 17(21):8862.
116. Musumeci O., Brady S., Rodolico C., et al. Recurrent rhabdomyolysis due to muscle beta-enolase deficiency: very rare or underestimated?. J. Neurol. 2014, 261(12):2424-2428.
117. Miyajima H., Takahashi Y., Suzuki M., Shimizu T., Kaneko E. Molecular characterization of gene expression in human lactate dehydrogenase-A. Neurology 1993, 43(7):1414-1419.
118. Woerle H.J., Meyer C., Dostou J.M., et al. Pathways for glucose disposal after meal ingestion in humans. Am. J. Physiol. Endocrinol. Metab. 2003, 284(4):E716-E725.
119. Barosa C., Silva C., Fagulha A., et al. Sources of hepatic glycogen synthesis following a milk-containing breakfast meal in healthy subjects. Metabolism 2012, 61(2):250-254.
120. Décombaz J., Jentjens R., Ith M., et al. Fructose and galactose enhance postexercise human liver glycogen synthesis. Med. Sci. Sports Exerc. 2011, 43(10):1964-1971.
121. Bergstrom J., Hultman E., Roch-Norlund A.E. Muscle glycogen synthetase in normal subjects. Basal values, effect of glycogen depletion by exercise and of a carbohydrate-rich diet following exercise. Scand. J. Clin. Lab. Invest. 1972, 29(2):231-236.
122. Kochan R.G., Lamb D.R., Lutz S.A., Perrill C.V., Reimann E.M., Schlender K.K. Glycogen synthase activation in human skeletal muscle: effects of diet and exercise. Am. J. Physiol. 1979, 236(6):E660-E666.
123. Koivisto V.A., Härkönen M., Karonen S.L., et al. Glycogen depletion during prolonged exercise: influence of glucose, fructose, or placebo. J. Appl. Physiol.(1985) 1985, 58(3):731-737.
124. Levine L., Evans W.J., Cadarette B.S., Fisher E.C., Bullen B.A. Fructose and glucose ingestion and muscle glycogen use during submaximal exercise. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 1983, 55(6):1767-1771.
125. Vukovich M.D., Costill D.L., Hickey M.S., Trappe S.W., Cole K.J., Fink W.J. Effect of fat emulsion infusion and fat feeding on muscle glycogen utilization during cycle exercise. J. Appl. Physiol.(1985) 1993, 75(4):1513-1518.
126. Ryan A.S., Katzel L.I., Prior S.J., McLenithan J.C., Goldberg A.P., Ortmeyer H.K. Aerobic exercise plus weight loss improves insulin sensitivity and increases skeletal muscle glycogen synthase activity in older men. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69(7):790-798.
127. Wallis G.A., Hulston C.J., Mann C.H., Roper H.P., Tipton K.D., Jeukendrup A.E. Postexercise muscle glycogen synthesis with combined glucose and fructose ingestion. Med. Sci. Sports Exerc. 2008, 40(10):1789-1794.
128. Jentjens R.L., van Loon L.J., Mann C.H., Wagenmakers A.J., Jeukendrup A.E. Addition of protein and amino acids to carbohydrates does not enhance postexercise muscle glycogen synthesis. J. Appl. Physiol. (1985) 2001, 91(2):839-846.
129. Detko E., O'Hara J.P., Thelwall P.E., et al. Liver and muscle glycogen repletion using 13C magnetic resonance spectroscopy following ingestion of maltodextrin, galactose, protein and amino acids. Br. J. Nutr. 2013, 110(5):848-855.
130. Di Camillo B., Eduati F., Nair S.K., Avogaro A., Toffolo G.M. Leucine modulates dynamic phosphorylation events in insulin signaling pathway and enhances insulin-dependent glycogen synthesis in human skeletal muscle cells. BMC Cell Biol. 2014, 15:9.
131. Johnson A.B., Argyraki M., Thow J.C., Cooper B.G., Fulcher G., Taylor R. Effect of increased free fatty acid supply on glucose metabolism and skeletal muscle glycogen synthase activity in normal man. Clin. Sci. (Lond.) 1992, 82(2):219-226.
132. Stephens F.B., Constantin-Teodosiu D., Laithwaite D., Simpson E.J., Greenhaff P.L. An acute increase in skeletal muscle carnitine content alters fuel metabolism in resting human skeletal muscle. J. Clin. Endocrinol. Metab. 2006, 91(12):5013-5018.
133. Preisler N., Haller R.G., Vissing J. Exercise in muscle glycogen storage diseases. J. Inherit. Metab. Dis. 2015, 38(3):551-563.